Jacob Adashek: Can Gilteritinib achieve a complete morphologic response in ALK-rearranged acute myeloid leukemia?

Jacob J. Adashek shared a post on LinkedIn:

“HOT OFF THE PRESS in Nature Portfolio with Johns Hopkins Kimmel Cancer Center

‘Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia‘

Gilteritinib is a potent ALK inhibitor and two inversion creates constitutively active ALK.

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia.

Authors: Jacob J. Adashek, Max Brodsky , Mark J. Levis”

Source: Jacob J. Adashek/LinkedIn

Jacob Adashek is the Agonist Cancer Therapies Section Editor at the National Cancer Institute (NCI). Previously, He was a medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital. With a focus on precision medicine, personalized therapies, and first-in-human clinical trials and being interested in biomarker-driven early-phase clinical trials, he has contributed to over 70 peer-reviewed articles in medical journals like Nature Clinical Reviews Oncology and JAMA Oncology. He has done clinical research at the City of Hope, specializing in genitourinary oncology, and remains an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.